Clinical Trials Directory

Trials / Completed

CompletedNCT01780948

Pharmacokinetic of Everolimus and Atorvastatin Co-administration

Drug Interaction and Pharmacokinetic Assessment of Everolimus When Coadministered With Atorvastatin in Renal Transplantation Recipient

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
18 (actual)
Sponsor
Chulalongkorn University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hypothesis : In renal transplantation recipient who received immunosuppressive drug "certican" and have hypercholesterolemia will get lipid lower drug-HMG Co-A reductase inhibitors. Because atorvastatin and everolimus have metabolism via Cytochrome P450 subfamily 3A4 both, so investigator made the hypothesis that when patients received everolimus with atorvastatin will change area under the time concentration curve of everolimus.

Detailed description

Population : Thai postrenal transplantation recipient who received everolimus and have hypercholesterolemia in posttransplantation clinic at Faculty of Medicine, Chulalongkorn University. Study Design : Experimental study, Two-sample crossover study Sample size calculation :N = 18 Primary outcome : 12-hour area under the time concentration curve of everolimus Secondary outcome : renal function (serum creatinine, creatinine clearance) Method : 1. Patients will random to everolimus or everolimus with atorvastatin 20 mg arm for 1 month. 2. Take blood sample for everolimus concentration at time 0,0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 hour 3. After first blood sample, patients will received everolimus only for 1 month (wash out period) 4. Patients will switch to another arm eg.patient who had received everolimus will switch to everolimus with atorvastatin 20 mg for 1 month 5. Take blood sample for everolimus concentration at time 0,0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 hour 6. Everolimus level will analyse for 12-hour AUC of everolimus.

Conditions

Interventions

TypeNameDescription
DRUGAtorvastatin 20 mgAdd atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg
DRUGEverolimusAdministration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.

Timeline

Start date
2012-09-01
Primary completion
2013-01-01
Completion
2013-01-01
First posted
2013-01-31
Last updated
2013-02-08

Locations

1 site across 1 country: Thailand

Source: ClinicalTrials.gov record NCT01780948. Inclusion in this directory is not an endorsement.